Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

January 9, 2023

https://www.globenewswire.com/news-release/2023/01/09/2585103/0/en/Reunion-Neuroscience-Inc-Completes-Interim-Data-Analysis-for-Phase-1-Clinical-Trial-with-Novel-Serotonergic-Psychedelic-RE104.html

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that the Company has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug. RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.  

Read more at globenewswire.com

Related news for (REUN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.